Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 21454698
Plaza-Menacho I, et al. (2011) Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism. J Biol Chem 286, 17292-302 21454698
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Ret (human) increase
PP1 Ret (human) no effect upon treatment-induced increase
imatinib Ret (human) no effect upon treatment-induced increase
sorafenib Ret (human) inhibit treatment-induced increase
NVP-TAE226 decrease

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Ret (human) increase
PP1 Ret (human) no effect upon treatment-induced increase
imatinib Ret (human) no effect upon treatment-induced increase
sorafenib Ret (human) inhibit treatment-induced increase
NVP-TAE226 decrease

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Ret (human) increase
PP1 Ret (human) no effect upon treatment-induced increase
imatinib Ret (human) no effect upon treatment-induced increase
sorafenib Ret (human) inhibit treatment-induced increase
NVP-TAE226 decrease

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Ret (human) increase
PP1 Ret (human) no effect upon treatment-induced increase
imatinib Ret (human) no effect upon treatment-induced increase
sorafenib Ret (human) inhibit treatment-induced increase
NVP-TAE226 decrease

Y576-p - FAK (human)
Modsite: RyMEDstyyKAsKGK SwissProt Entrez-Gene
Orthologous residues
FAK (human): Y576‑p, FAK iso2 (human): Y424‑p, FAK iso5 (human): Y576‑p, FAK (mouse): Y576‑p, FAK iso2 (mouse): Y607‑p, FAK iso4 (mouse): Y576‑p, FAK iso9 (mouse): , FAK (rat): Y576‑p, FAK (chicken): Y576‑p, FAK iso5 (chicken):
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Ret (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Ret (human) activation of upstream enzyme, transfection of wild-type enzyme, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Ret (human) increase
PP1 Ret (human) no effect upon treatment-induced increase
imatinib Ret (human) no effect upon treatment-induced increase
sorafenib Ret (human) inhibit treatment-induced increase
NVP-TAE226 decrease

Y577-p - FAK (human)
Modsite: yMEDstyyKAsKGKL SwissProt Entrez-Gene
Orthologous residues
FAK (human): Y577‑p, FAK iso2 (human): Y425‑p, FAK iso5 (human): Y577‑p, FAK (mouse): Y577‑p, FAK iso2 (mouse): Y608‑p, FAK iso4 (mouse): Y577‑p, FAK iso9 (mouse): , FAK (rat): Y577‑p, FAK (chicken): Y577‑p, FAK iso5 (chicken):
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Ret (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Ret (human) activation of upstream enzyme, transfection of wild-type enzyme, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Ret (human) increase
PP1 Ret (human) no effect upon treatment-induced increase
imatinib Ret (human) no effect upon treatment-induced increase
sorafenib Ret (human) inhibit treatment-induced increase
NVP-TAE226 decrease

Y925-p - FAK (human)
Modsite: DRsNDkVyENVtGLV SwissProt Entrez-Gene
Orthologous residues
FAK (human): Y925‑p, FAK iso2 (human): Y752‑p, FAK iso5 (human): Y938‑p, FAK (mouse): Y925‑p, FAK iso2 (mouse): Y956‑p, FAK iso4 (mouse): Y928‑p, FAK iso9 (mouse): Y233‑p, FAK (rat): Y928‑p, FAK (chicken): Y926‑p, FAK iso5 (chicken): Y232‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Ret (human)

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Ret (human) increase
PP1 Ret (human) no effect upon treatment-induced increase
imatinib Ret (human) no effect upon treatment-induced increase
sorafenib Ret (human) inhibit treatment-induced increase

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Ret (human) increase
PP1 Ret (human) no effect upon treatment-induced increase
imatinib Ret (human) no effect upon treatment-induced increase
sorafenib Ret (human) inhibit treatment-induced increase

Y182-p - P38A (human)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Ret (human) increase
PP1 Ret (human) no effect upon treatment-induced increase
imatinib Ret (human) no effect upon treatment-induced increase
sorafenib Ret (human) inhibit treatment-induced increase

T185-p - P38A (human)
Modsite: EMtGyVAtRWYRAPE SwissProt Entrez-Gene
Orthologous residues
P38A (human): T185‑p, P38A iso2 (human): T185‑p, P38A (mouse): T185‑p, P38A iso3 (mouse): T185‑p, P38A (rat): T185‑p, P38A (salmonid): T186‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Ret (human) increase
PP1 Ret (human) no effect upon treatment-induced increase
imatinib Ret (human) no effect upon treatment-induced increase
sorafenib Ret (human) inhibit treatment-induced increase

Y905-p - Ret (human)
Modsite: DVyEEDsyVKRsQGR SwissProt Entrez-Gene
Orthologous residues
Ret (human): Y905‑p, Ret iso2 (human): Y905‑p, Ret iso3 (human): Y429‑p, Ret (mouse): Y906‑p, Ret iso2 (mouse): Y906‑p, Ret iso4 (mouse): , Ret (rat): Y906‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE FAK (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE FAK (human) transfection of constitutively active enzyme, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Ret (human) increase
PP1 Ret (human) no effect upon treatment-induced increase
imatinib Ret (human) no effect upon treatment-induced increase
sorafenib Ret (human) inhibit treatment-induced increase
NVP-TAE226 decrease

Y981-p - Ret (human)
Modsite: DNCSEEMyRLMLQCW SwissProt Entrez-Gene
Orthologous residues
Ret (human): Y981‑p, Ret iso2 (human): Y981‑p, Ret iso3 (human): Y505‑p, Ret (mouse): Y982‑p, Ret iso2 (mouse): Y982‑p, Ret iso4 (mouse): , Ret (rat): Y982‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Ret (human) increase
PP1 Ret (human) no effect upon treatment-induced increase
imatinib Ret (human) no effect upon treatment-induced increase
sorafenib Ret (human) inhibit treatment-induced increase

Y1062-p - Ret (human)
Modsite: TWIENkLyGMsDPNW SwissProt Entrez-Gene
Orthologous residues
Ret (human): Y1062‑p, Ret iso2 (human): Y1062‑p, Ret iso3 (human): Y586‑p, Ret (mouse): Y1063‑p, Ret iso2 (mouse): Y1063‑p, Ret iso4 (mouse): , Ret (rat): Y1063‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Ret (human) increase
PP1 Ret (human) no effect upon treatment-induced increase
imatinib Ret (human) no effect upon treatment-induced increase
sorafenib Ret (human) inhibit treatment-induced increase
NVP-TAE226 decrease

Y419-p - Src (human)
Modsite: RLIEDNEytARQGAk SwissProt Entrez-Gene
Orthologous residues
Src (human): Y419‑p, Src iso2 (human): Y425‑p, Src (mouse): Y424‑p, Src iso2 (mouse): Y418‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Ret (human) increase
PP1 Ret (human) no effect upon treatment-induced increase
imatinib Ret (human) no effect upon treatment-induced increase
sorafenib Ret (human) inhibit treatment-induced increase

Y705-p - STAT3 (human)
Modsite: DPGsAAPyLktKFIC SwissProt Entrez-Gene
Orthologous residues
STAT3 (human): Y705‑p, STAT3 iso2 (human): Y704‑p, STAT3 iso3 (human): Y705‑p, STAT3 (mouse): Y705‑p, STAT3 iso2 (mouse): Y705‑p, STAT3 iso3 (mouse): Y704‑p, STAT3 (rat): Y705‑p, STAT3 (cow): Y705‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Ret (human) increase
PP1 Ret (human) no effect upon treatment-induced increase
imatinib Ret (human) no effect upon treatment-induced increase
sorafenib Ret (human) inhibit treatment-induced increase